From clinical trials to clinical practice: Therapeutic cancer vaccines for the treatment of prostate cancer - Abstract

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20912, USA.

 

Therapeutic options for patients with metastatic castration-resistant prostate cancer are increasing, spurring an urgent need to better understand which treatments are best for individual patients. The recent approval of a first-in-class agent, sipuleucel-T, has intensified this need. This therapeutic cancer vaccine has demonstrated a survival advantage in two Phase III trials, but does not alter progression in the short term. Therefore, a new therapeutic approach for patients with metastatic castration-resistant prostate cancer is taking shape, based on broader understanding of available therapies. This new clinical approach seeks to maximize patient benefit from treatment, minimize associated toxicities, and may have far-reaching implications for other therapeutic cancer vaccines currently in clinical development.

Written by:
Madan RA, Aragon-Ching JB, Gulley JL, Dahut WL.   Are you the author?

Reference: Expert Rev Vaccines. 2011 Jun;10(6):743-53.
doi: 10.1586/erv.11.70

PubMed Abstract
PMID: 21692697

UroToday.com Prostate Cancer Section